登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由江苏省人民医院(南医大一附院)牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06594432,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 80 岁;性别:不限
登记记录的入选字段
Patients with pathologically confirmed, previously untreated diffuse large B-cell lymphoma (DLBCL) who are CSF-ctDNA positive for secondary CNS lymphoma (SCNSL);
入选标准第 2 条
MRI or CT of the brain showing substantial lesions in the central nervous system; patients with only meningeal lesions must have CSF cytology confirming lymphoma cells and/or imaging findings consistent with CSF examination;
入选标准第 3 条
Received targeted therapy within 10 days before starting the study drug, or systemic chemotherapy, radiotherapy, or antibody therapy within 3 weeks before starting the study drug;
排除标准第 2 条
Previous chemotherapy with unresolved toxicity (toxicity not resolved to ≤ grade 1 according to NCI-CTCAE 5.0, except for alopecia, absolute neutrophil count (ANC), and platelets);
排除标准第 6 条
Patients who have not completed 4 weeks after major organ surgery;
排除标准第 11 条
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-3;
入选标准第 4 条
Organ function levels meeting the following requirements:Absolute neutrophil count ≥1.5×10\^9/L, platelets ≥75×10\^9/L, hemoglobin ≥90g/L (if bone marrow is involved, platelets ≥50×10\^9/L).
入选标准第 5 条
Liver function: ALT and AST ≤2.5 times the upper limit of normal, total bilirubin ≤2 times the upper limit of normal.
入选标准第 6 条
Abnormal liver function (total bilirubin \>2 times the normal value, ALT or AST \>2.5 times the normal value), abnormal renal function (serum creatinine \>1.5 times the normal value);
排除标准第 3 条
Patients with active HBV, HCV, and HIV infections;
排除标准第 9 条
Pregnant or lactating women and patients of childbearing potential who are unwilling to use contraception;
排除标准第 13 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06594432,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age ≥18 years and ≤80 years, regardless of gender; Patients with pathologically confirmed, previously untreated diffuse large B-cell lymphoma (DLBCL) who are CSF-ctDNA positive for secondary CNS lymphoma (SCNSL); MRI or CT of the brain showing substantial lesions in the central nervous system; patients with only meningeal lesions must have CSF cytology confirming lymphoma cells and/or imaging findings consistent with CSF examination; Eastern Cooperative Oncology Group (ECOG) performance status score of 0-3; Organ function levels meeting the following requirements:Absolute neutrophil count ≥1.5×10\^9/L, platelets ≥75×10\^9/L, hemoglobin ≥90g/L (if bone marrow is involved, platelets ≥50×10\^9/L). Liver function: ALT and AST ≤2.5 times the upper limit of normal, total bilirubin ≤2 times the upper limit of normal.排除标准:Exclusion Criteria:
Previous treatment with BTK inhibitors; Received targeted therapy within 10 days before starting the study drug, or systemic chemotherapy, radiotherapy, or antibody therapy within 3 weeks before starting the study drug; Abnormal liver function (total bilirubin \>2 times the normal value, ALT or AST \>2.5 times the normal value), abnormal renal function (serum creatinine \>1.5 times the normal value); Currently have clinically significant active cardiovascular disease, such as uncontrolled arrhythmias, congestive heart failure, any grade 3 or 4 heart disease as determined by the New York Heart Association (NYHA) functional classification, or a history of myocardial infarction within 6 months before screening; QTcF \>450 msecs or other significant ECG abnormalities, including second-degree type II atrioventricular (AV) block or third-degree AV block; Previous chemotherapy with unresolved toxicity (toxicity not resolved to ≤ grade 1 according to NCI-CTCAE 5.0, except for alopecia, absolute neutrophil count (ANC), and platelets); Patients with active bleeding; Patients with active infections or persistent fever within 14 days before enrollment (excluding tumor-related fever); Patients with active HBV, HCV, and HIV infections; Patients with serous cavity effusion; Patients who have not completed 4 weeks after major organ surgery; Patients receiving strong inhibitors or strong inducers of cytochrome P450 family 3 subfamily A (CYP3A); Pregnant or lactating women and patients of childbearing potential who are unwilling to use contraception; Patients with mental disorders/unable to obtain informed consent; Patients who abuse drugs or have long-term alcoholism that affects the evaluation of trial results; Patients deemed unsuitable for participation in this study by the investigator.
引自 ClinicalTrials.gov, NCT06594432, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06594432,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。